Invivyd's (IVVD) "Buy" Rating Reaffirmed at HC Wainwright

Key Points

• Analysts at HC Wainwright have reaffirmed their "buy" rating for Invivyd (NASDAQ: IVVD) with a price target of $5.00, suggesting a potential upside of 385.44% from the company's previous close.
• Invivyd reported a loss per share of ($0.12) in its latest earnings, missing the consensus estimate by ($0.08) and generating only $11.79 million in revenue, significantly below expectations.
• Insider trading has shown some activity, with insider Jill Andersen selling 49,402 shares at an average price of $0.57, indicating a 36.91% decrease in their position.

Invivyd (NASDAQ:IVVD - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $5.00 price target on the stock. HC Wainwright's target price would indicate a potential upside of 385.44% from the company's previous close.

Separately, D. Boral Capital cut their price objective on shares of Invivyd from $3.00 to $1.00 and set a "buy" rating on the stock in a report on Monday. One research analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company's stock. According to data from MarketBeat, Invivyd presently has an average rating of "Buy" and an average target price of $3.18.

Invivyd Stock Up 84.0%

NASDAQ:IVVD opened at $1.03 on Wednesday. The company has a fifty day moving average of $0.73 and a 200-day moving average of $0.80. The firm has a market capitalization of $123.75 million, a P/E ratio of -1.12 and a beta of 0.51. Invivyd has a twelve month low of $0.35 and a twelve month high of $2.74.

Invivyd (NASDAQ:IVVD - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.08). Invivyd had a negative net margin of 238.33% and a negative return on equity of 177.89%. The company had revenue of $11.79 million during the quarter, compared to the consensus estimate of $23.16 million. On average, analysts anticipate that Invivyd will post -1.64 EPS for the current fiscal year.

Insider Buying and Selling at Invivyd

In related news, insider Jill Andersen sold 49,402 shares of the business's stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $0.57, for a total value of $28,159.14. Following the transaction, the insider directly owned 84,446 shares of the company's stock, valued at approximately $48,134.22. The trade was a 36.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 277,654 shares of company stock valued at $167,215. 25.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Invivyd

Several institutional investors have recently added to or reduced their stakes in IVVD. Catalyst Funds Management Pty Ltd purchased a new stake in Invivyd during the second quarter valued at about $27,000. Vanguard Personalized Indexing Management LLC increased its position in shares of Invivyd by 238.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock valued at $29,000 after buying an additional 28,146 shares during the period. Jane Street Group LLC increased its position in shares of Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock valued at $52,000 after buying an additional 87,358 shares during the period. Barclays PLC increased its position in shares of Invivyd by 7.8% during the fourth quarter. Barclays PLC now owns 127,180 shares of the company's stock valued at $56,000 after buying an additional 9,207 shares during the period. Finally, Nuveen LLC bought a new stake in shares of Invivyd during the first quarter valued at about $65,000. 70.36% of the stock is owned by hedge funds and other institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.